Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2003
10/16/2003CA2478932A1 Large scale methods of producing adenovirus and adenovirus seed stocks
10/16/2003CA2478523A1 Matrix for sustained, invariant and independent release of active compounds
10/16/2003CA2478340A1 Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa
10/16/2003CA2478227A1 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
10/16/2003CA2477298A1 Use of biomolecular targets in the treatment and visualization of brain tumors
10/16/2003CA2476545A1 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections
10/16/2003CA2462708A1 Diazabicyclo alkane derivatives with nk1 antagonistic activity
10/15/2003EP1352956A1 Inhibition of DNA methyltransferase
10/15/2003EP1352910A1 New analogs of nitrobenzylthioinosine
10/15/2003EP1352907A1 Processes for preparing calanolide a and intermediates thereof
10/15/2003EP1352903A1 Preventive or remedial agent for allergic disease and medical water-based liquid preparation, eye drop, and nasal drop
10/15/2003EP1352897A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352896A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352895A2 Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases
10/15/2003EP1352661A1 Injections for endoscopy
10/15/2003EP1352660A1 Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a nsaid
10/15/2003EP1352659A1 Combination drugs
10/15/2003EP1352658A1 Preventives or remedies for endometriosis
10/15/2003EP1352656A2 Combination therapy using a TNF binding protein for treating TNF-mediated diseases
10/15/2003EP1352655A1 Remedies for bone marrow suppression and infectious diseases and white blood cell count elevating agents
10/15/2003EP1352654A1 Famotidine injections
10/15/2003EP1352653A1 Dihydrofuran cyclic tanshintones used in treating hyperammonemia and hepatic encephalopathy
10/15/2003EP1352652A1 Fat composition for oral or enteral administration and hexacosanoic acid depressant
10/15/2003EP1352651A2 Novel use of orexin receptor antagonists
10/15/2003EP1352650A1 Inhibitors against the production and release of inflammatory cytokines
10/15/2003EP1352647A1 Controlled-release sedative hypnotic compositions and method related thereto
10/15/2003EP1352646A2 Lozenge containing ambroxol
10/15/2003EP1352638A1 Cosmetics
10/15/2003EP1352629A1 Use of a pyridine-dicarboxylic acid derivative or a salt thereof to stimulate or induce keratinic fiber growth and/or to prevent its loss
10/15/2003EP1352627A2 Reduction of hair growth
10/15/2003EP1352084A2 Method for identifying modulators of bace
10/15/2003EP1352077A2 Materials and methods relating to protein aggregation in neurodegenerative disease
10/15/2003EP1352065A2 Polypetides and nucleic acids encoding same
10/15/2003EP1352061A2 Method for inhibiting the expression of a target gene
10/15/2003EP1352056A2 Polypeptides
10/15/2003EP1351975A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases
10/15/2003EP1351973A1 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
10/15/2003EP1351972A1 Lipids comprising an aminoxy group
10/15/2003EP1351971A2 Compounds useful for treating hypertriglyceridemia
10/15/2003EP1351968A1 Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
10/15/2003EP1351967A2 Compositions and methods for the therapy and diagnosis of lung cancer
10/15/2003EP1351966A1 Improved specificity in treatment of diseases
10/15/2003EP1351963A1 A process for the synthesis of atorvastatin form v and phenylboronates as intermediate compounds
10/15/2003EP1351962A2 Thienopyrimidine
10/15/2003EP1351961A1 Substituted indolines as 5-ht receptor ligands
10/15/2003EP1351960A1 Improved preparation of (4r, 5s, 6s)-3-[[(2r,3r)-2-[[[(s)-2-amino-3-methyl-1-oxobutyl]methyl]tetrahydro-3-furanyl]thio]-6-[(r)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
10/15/2003EP1351959A1 Novel pleuromutilin derivatives
10/15/2003EP1351958A1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
10/15/2003EP1351957A1 Chemical derivatives and their use as anti-telomerase agent
10/15/2003EP1351956A1 Semicarbazides and their uses as cyclin dependent kinase inhibitors
10/15/2003EP1351955A1 Excitatory amino acid receptor antagonists
10/15/2003EP1351954A1 Farnesyl transferase inhibiting 4-heterocyclyl-quinoline and quinazoline derivatives
10/15/2003EP1351953A1 Quinoline derivatives as nk-3 antagonists
10/15/2003EP1351951A2 Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
10/15/2003EP1351950A2 Isoindolyl and isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders
10/15/2003EP1351942A1 Novel 2,3-benzodiazepine derivatives and pharmaceutical compositions containing the same as the active ingredient
10/15/2003EP1351941A1 Bisaryl derivatives having fsh receptor modulatory activity
10/15/2003EP1351940A1 Substituted quinolines for the treatment of protozoan and retrovirus co-infections
10/15/2003EP1351938A1 Phenyl derivatives
10/15/2003EP1351937A1 Aryl piperidine derivatives as inducers of ldl-receptor expression
10/15/2003EP1351936A1 Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
10/15/2003EP1351935A1 Aryl piperidine derivatives as inducers of ldl-receptor expression
10/15/2003EP1351934A1 Naphthalene derivatives which bind to the ep4 receptor
10/15/2003EP1351933A1 Il-8 receptor antagonists
10/15/2003EP1351932A2 N-substituted 2-cyanopyrrolidines and their use as antidiabetic agents
10/15/2003EP1351930A2 Protease inhibitors
10/15/2003EP1351929A1 Nitric oxide synthase inhibitor phosphate salt
10/15/2003EP1351928A2 Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use
10/15/2003EP1351925A1 Prodrugs of excitatory amino acids
10/15/2003EP1351924A2 Diamines as modulators of chemokine receptor activity
10/15/2003EP1351919A1 Retinol derivatives and process for preparing same
10/15/2003EP1351916A2 Ether compounds and compositions for cholesterol management and related uses
10/15/2003EP1351743A2 Liquid composition comprising an alcohol
10/15/2003EP1351702A1 Trem-1 splice variant for use in modifying immune responses
10/15/2003EP1351701A2 Active metabolite of antifungal compound
10/15/2003EP1351698A2 Herbal composition for angina pectoris, method to prepare same and uses thereof
10/15/2003EP1351695A1 Camptothecin compounds with a sulfhydryl group
10/15/2003EP1351694A1 Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
10/15/2003EP1351693A1 Novel method and compositions for local treatment of meniere's disease, tinnitus and/or hearing loss
10/15/2003EP1351692A1 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
10/15/2003EP1351691A1 Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
10/15/2003EP1351690A2 Method of treatment of dopamine-related dysfunction through administration of a full d1 dopamine receptor agonist and with no induction of tolerance
10/15/2003EP1351689A2 Derivatives of the (3s, 4ar, 6s, 8ar) 6-phenylamino-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid as excitatory amino acid receptor antagonists for the treatment of neurological disorders and neurodegenerative diseases
10/15/2003EP1351688A1 Urotensin-ii receptor antagonists
10/15/2003EP1351687A2 Urotensin-ii receptor antagonists
10/15/2003EP1351686A2 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
10/15/2003EP1351685A2 Stabilized formulation of selective ligands of retinoic acid gamma-receptors
10/15/2003EP1351684A2 Compounds and methods for promoting smoking cessation
10/15/2003EP1351683A2 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
10/15/2003EP1351682A1 Regulation of lipids and/or bone density and compositions therefor
10/15/2003EP1351681A2 Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
10/15/2003EP1351680A2 Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity
10/15/2003EP1351679A2 Method and composition for the treatment of diabetic neuropathy
10/15/2003EP1351678A2 Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
10/15/2003EP1351677A2 Method for treating cancer
10/15/2003EP1351676A1 Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis
10/15/2003EP1351675A2 Alpha-difluoromethylornithine (dfmo) use in the human prostate
10/15/2003EP1351674A1 Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
10/15/2003EP1351673A1 Compositions of stable t 3? and methods of use thereof
10/15/2003EP1351672A1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders
1 ... 5310 5311 5312 5313 5314 5315 5316 5317 5318 5319 5320 5321 5322 5323 5324 5325 5326 5327 5328 5329 5330 ... 7860